Company intelligence / Profile preview

Gensaic

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Gensaic has not reported clinical results; the company remains preclinical, focusing on platform development and partnerships, particularly for tissue-selective intracellular delivery using engineered phage particles and AI-designed proteins[1][3].

Therapeutic areas: Metabolic DisordersPulmonologyCardiovascularOther
Modalities: Gene therapyPhage-derived particle deliveryRNA therapy (siRNA payloads)
Industry: Biotech

Partnerships

Novo Nordisk (up to $354 million per target collaboration for tissue-selective delivery in cardiometabolic diseases)[3]Cystic Fibrosis Foundation (funding/support for lung delivery platform development)[2]

Beyond the preview

Go deeper on Gensaic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gensaic.

Explore the full profile